
In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.
In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.






